Current challenges in three-dimensional bioprinting heart tissues for cardiac surgery. by Roche, CD et al.
Cite this article as: Roche CD, Brereton RJL, Ashton AW, Jackson C, Gentile C. Current challenges in three-dimensional bioprinting heart tissues for cardiac surgery.
Eur J Cardiothorac Surg 2020;58:500–10.
Current challenges in three-dimensional bioprinting heart
tissues for cardiac surgery
Christopher D. Roche a,b,c,d, Russell J.L. Breretonb, Anthony W. Ashtona, Christopher Jacksona and
Carmine Gentile a,c,*
a Northern Clinical School of Medicine, University of Sydney, Kolling Institute, St Leonards, Sydney, NSW, Australia
b Department of Cardiothoracic Surgery, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia
c Department of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney (UTS), Ultimo, Sydney, NSW, Australia
d Department of Cardiothoracic Surgery, University Hospital of Wales, Cardiff, UK
* Corresponding author. Department of Biomedical Engineering, Faculty of Engineering and IT, Building 11, 81 Broadway, Ultimo, NSW 2007, Australia. Tel: +61-2-
95144502; e-mail: carmine.gentile@uts.edu.au (C. Gentile).
Received 29 November 2019; received in revised form 27 January 2020; accepted 18 February 2020
Summary: Previous attempts in cardiac bioengineering have failed to provide tissues for cardiac regeneration. Recent advances in 3-di-
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INTRODUCTION
With recent advances in the technological triad of induced pluri-
potent stem cells (iPSCs), 3-dimensional (3D) cardiac microtissues
(referred to as ‘cardiospheres’, ‘cardiac spheroids’, ‘cardiac orga-
noids’ [1]) and 3D bioprinting, the enticing prospect has arisen of
fabricating cardiac tissues to replace diseased native tissues and
to regenerate damaged hearts [2–10].
The incentive for this is strong: in the UK, 30–40% of patients
diagnosed with heart failure will die within 1 year of diagnosis
with an additional 10% annually thereafter [11]. Moreover, the
period before death is associated with a severe disease burden
and reduced quality of life [12]. For end-stage patients, the gold
standard treatment is a heart transplant [13]. However, this is not
suitable for all, carrying significant morbidity and a global mor-
tality rate of 15% and 25% at 1 and 5 years, respectively [14]. In
addition, there is significant urgency to find a treatment, which is
not waiting list dependent, for those patients awaiting a donor.
Last year, patients on the Australian heart transplant list had a
56% chance of being transplanted by the end of the year, a 31%
chance of being carried over to next year and a 3.5% chance of
dying whilst waiting [15]. For the UK, the equivalent figures were
29% transplanted, 55% carried over and 3% dying [16]. The me-
dian waiting time for an adult categorized as non-urgent on the
UK heart transplant list approaches 3 years [16].
In this context, several new approaches have been developed
for regenerating the myocardium [4–7, 9, 10, 17–23]. Recent
studies have demonstrated the feasibility for 3D bioprinting of
myocardial tissues from patient-derived stem cells; however,
limitations of such approaches still remain, including full vascu-
larization and synchronous contractile activity [5, 9, 10]. This re-
view explores why this is difficult and why it is worth pursuing.
CHALLENGES: OVERVIEW
General challenges limiting engineered cardiac tissues include (i)
limited tissue survival following transplantation; (ii) limited ability
to generate tissue of adequate size; (iii) optimizing the mix of car-
diac cell types; (iv) cell sourcing from patients; (v) the immature
phenotype of stem cell-derived cardiac cells; (vi) safety concerns
for potentially undifferentiated stem cells; and (vii) immunogen-
icity requiring immunosuppression (Table 1).
Other considerations particularly pertaining to myocardial
generation are the need for: (i) a vascular network spanning
many orders of magnitude from arterial to capillary level and (ii)
a synchronously contractile, electrically conductive tissue.
STEM CELLS AND THEIR NICHE
It is not feasible to use mature, differentiated, adult myocardial
cells for the therapeutic regeneration of myocardial tissue, as
these cells exhibit reduced viability and proliferation when
engrafted [17]. Instead, current approaches prefer stem cells that
can be coaxed into desired, fully differentiated forms in response
to microenvironmental cues, which can be controlled [4–6]. With
the exception of bone marrow transplant, stem cells have not ful-
filled their expected clinical potential in regenerative medicine
[24]. However, the advent of iPSCs provides a promising cell
source for regeneration, including 3D bioprinting of myocardial
tissue [5, 9, 25, 26].
It has long been understood that the stem cell microenviron-
ment, called the ‘niche’, provides cues that determine how tissues
develop and function [27–29]. These cues include extracellular
matrix (ECM) proteins, temperature and oxygen, which are
known to influence tissue growth and stem cell behaviour [28].
Cells in a suboptimal niche may not survive and will perform
poorly [28]. Cells implanted directly into diseased host myocar-
dium exhibit poor survival and ability to organize into functional
Table 1: Challenges for the development of bioengineered cardiac tissues
General Vascularization Contractility
Cell survival postimplantation in diseased
environment
Observation of appropriate vascular tissue matur-
ation without cell destruction or alteration
Integration with host depolarization-repolarization
wave without arrhythmogenicity
Host immune response to implanted material Functional validation of the bioprinted vascular tree Engineering the correct electrochemical environment
for cardiomyocyte maturation
Possible biological scaffold needed with its
own biofabrication challenges
Surgical integration with pre-existing host
vasculature
Coculture with other cell types for appropriate matur-
ation of stem cell-derived cardiomyocytes
Correct cell mix mimicking mature myocardial
tissue
Vascular lumen generation and integration of hier-
archical arteriovenous tree segments
Optimization of 3D culture techniques required for
formation of cell–cell connections
Expanding cells to an appropriately high
number
Stem cell selection for clinically useable vascular cell
source
Reproducibility and scalability to meet
demand
Time requirement for vascular tissue maturation
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tissues, as they lack the appropriate microenvironment [17, 30].
The native heart contains 2 billion cardiomyocytes (CMs) and
many more of other cell types [31]. The exact cardiac cell ratio is
not universally agreed upon; however, fully differentiated adult
human ventricular myocardium contains 33% CMs, 24% endo-
thelial cells (ECs) and 43% other cells (including fibroblasts) [32].
To provide a 3D microenvironment for cells to grow before their
transplantation, they have been cultured as 3D patches [4, 6, 22].
To further improve cell patch survival, these have been delivered
either under host pericardium [33] or matured on vascular host
omental tissue before transfer to the epicardium [34].
In addition to the niche, it is important to consider that differ-
ent stem cell types present their own unique challenges (Table 2)
[29].
‘Embryonic stem cells’ (ESCs) are pluripotent (i.e. they may dif-
ferentiate into mature cells of any of the 3 original germ cell
layers), do not undergo senescence in culture and can self-renew
indefinitely [29]. However, whilst harvesting from an embryo
raises ethical concerns, the host would also require immunosup-
pression from their implantation [29, 33] and there is a risk of
developing malignancy [29, 35].
‘Multipotent adult stem cells’, such as mesenchymal stem cells
from either bone marrow-mesenchymal stem cells or adipose tis-
sue-mesenchymal stem cells, could be readily isolated from the
host [29]. This eliminates ethical concerns, and as autografts,
there is no need for immunosuppression [29]. However, unlike
ESCs, adult stem cells have a limited differentiation repertoire, a
finite ability to self-renew and undergo senescence during
in vitro expansion [29].
Alternatively, somatic cells (skin/blood/urine) can be reprog-
rammed into iPSCs by transfecting them with a variety of tran-
scription factors [25, 26]. Like adult stem cells, autologous iPSCs
are patient specific and not isolated from an embryo [29]. Yet,
like ESCs, they self-renew without undergoing senescence and
can be coaxed to differentiate into almost any mature cell
phenotype in culture [26, 29, 36]. However, iPSCs present the risk
of teratoma formation when transplanted if not fully differenti-
ated [29]. An additional risk comes from using a virus to transfect
the stem cell factors, which may place the patient at the risk of
malignancy [25]. As an alternative, they can be reprogrammed
using a non-integrating RNA vector and without the use of a viral
vector [25].
3-DIMENSIONAL BIOPRINTING AND BIOINK
CHALLENGES
The definition of biofabrication for regenerative medicine is: ‘the
automated generation of biologically functional products with
structural organization from living cells, bioactive molecules,
biomaterials, cell aggregates such as microtissues, or hybrid cell-
material constructs, through bioprinting or bioassembly and
subsequent tissue maturation processes’ [37].
In this process, the 3D bioprinter is used to deposit bioink(s) in
hydrogels to generate viable and functional tissues, with the
end product controlled by the 3D bioprinting platform used [38].
For cardiac tissue, some of the most common systems use
extrusion-based bioprinters with pneumatic or screw-driven
Figure 1: Extrusion-based 3D bioprinting and cell viability. (A) Four-nozzle extrusion 3D bioprinting system using pneumatic force to extrude 4 different bioinks. In
this example, bioinks are extruded directly into a crosslinker solution, which acts on the bioink to create bonds within the bioprinted structure to retain its shape. (B)
Downward arrows with greater size indicate greater velocity centrally in the bioink and lower velocity at the periphery, which is in contact with the chamber wall.
Upward arrows show resulting shear stress on cells in bioink during 3D bioprinting. Greater shear at the periphery results in stressed cells (orange) and some dead cells
(red). Shear stress can be reduced by slowing down the velocity of extrusion, which is readily controlled in 3D bioprinting (reproduced with permission from Blaeser
et al. [18]). 3D: 3-dimensional.
Table 2: Limitations of using stem cells for 3D bioprinting
myocardial tissue




Adult Finite capacity for self-renewal
Limited mature cell types
Senescence in culture
Induced pluripotent Teratoma formation
3D: 3-dimensional.
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rotational force to move cellular bioink through a nozzle [3]. The
bioprinting method chosen is critical to meet the challenge of
delivering cells with minimal shear stress and avoid damaging
them in the process (Fig. 1) [18]. A variety of approaches, bio-
printers, bioinks and hydrogels to print cells into 3D myocardium
have been explored [3, 5].
Ideal bioinks for cardiac regeneration should mimic the native
3D myocardial microenvironment [6, 30]. Bioinks based on car-
diac tissue spheroids (which are scaffold free, self-sustainable cell
aggregates with a defined diameter and cell number) have been
used as building blocks in this process (Fig. 2) [20, 30, 39].
Optimizing cell-specific challenges should be considered when
creating cardiac spheroids in bioinks for heart tissue. This
includes a clinically relevant scale-up of cell numbers for trans-
plantable bioprinted heart tissues [3, 40]. In addition, mature
adult CMs cannot be used for spheroid-based bioinks as they
have low adhesive properties and do not form spheroid cultures
[41], whereas proliferating neonatal and iPSC-derived CMs (iPSC-
CMs) form spheroids within a few days [30]. Furthermore, add-
ition of more adhesive cells to the cellular mix within a spheroid,
such as cardiac fibroblasts (CFs), reduces the time for spheroid
formation [42]. ECs are a third important cell type found in the
human heart, and in vitro cardiac spheroids have been generated
using a ratio of primary adult CMs:ECs:CFs of 1:3:6, which was
optimal for adult CM viability, whereas for CMs derived from
iPSCs, a ratio of 2:1:1 was optimal for iPSC-CMs, ECs and CFs, re-
spectively [36, 42].
The use of preformed vascularized microtissues such as sphe-
roids for 3D bioprinting offers the prospect of overcoming many
bioink cell-related challenges for tissue engineering of viable
and functional myocardium [6, 43]. This includes, but is not limited
to, generating a vascular system within the bioink and better inte-
gration of physiological contractile function, including speed of
contraction, contraction amplitude and calcium transients [1, 44].
In addition to the cellular component, the hydrogel used to
support cells in bioink plays a major role in overall patch
Figure 2: Three-dimensional cardiac microtissue generation and physiology. (A) Standard 2-dimensional cell culture of human-induced pluripotent stem cell-derived
cardiomyocytes. (B) Single (200 lm diameter) cardiac spheroid microtissue—a 3-dimensional aggregate of cardiac cells with ability to control spheroid size and cell
number and optimize cell–cell interactions, 3-dimensional mechanical signals and extracellular support. (C) Two methods for generating cardiac spheroids: U-shaped
non-adhesive wells (top panel) and hanging drop cultures (bottom panel). (D) Two types of field pacing chambers for providing electrical stimulation to spheroids for
the optimal maturation of cardiomyocyte phenotype: a perfusion chamber (above) and culture dish (below) with electrodes to allow for field potential stimulation
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geometry, size, survival and function by better mimicking the
mechanical properties of the native ECM [45]. Hydrogel/bioink
composition determines important characteristics such as bio-
compatibility, biodegradability, paracrine signalling, non-
immunogenicity and stiffness, all of which present optimization
challenges [46–48]. To date, the formulation of cardiac bioinks
with optimal chemical–mechanical properties to better control
the cardiac niche has not been defined [46, 48]. The requirement
for a cell-friendly, flowing bioink limits other factors such as the
precision and resolution of the print, although this may be
improved by applying microfluidic devices to the extrusion noz-
zles of bioprinters [9, 49]. Whilst the bioink must flow well during
the print, it should also be mechanically robust and yet still allow
for the tissue to remodel and the cells to interact in the post-
printing phase [46].
Several hydrogels have been tested for cardiac tissues, either
using natural materials (such as decellularized cardiac ECM [46]
and gelatin-based hydrogels combined with fibrinogen, alginate
or hyaluronan [47]) or synthetic-origin materials (such as polyur-
ethane) [50]. Decellularized cardiac ECM promotes angiogenesis
and cell proliferation but cannot be easily isolated from the same
donor heart [46]. Gelatin has excellent rheological properties and
biodegradability, but its use is highly temperature dependent
[47]. Electrically conductive polymeric hydrogels such as
poly(ethylenedioxythiophene) allow for improved cell electroac-
tivity, whilst they present undesired properties such as increased
hydrophobicity and reduced elasticity [45, 51]. Other hydrogels
may present cell-specific paracrine signalling factors [48].
Therefore, the challenges associated with engineering the optimal
hydrogel are of paramount importance and should address sev-
eral chemical and biomechanical parameters.
VASCULARIZATION
Another major challenge for creating a cardiac patch is engineer-
ing a hierarchical vascular tree (Table 1) [10, 39]. The maximum
tissue diameter without the development of a necrotic core
varies since it depends on cell-specific oxygen consumption, but
it generally is common in any cardiac tissue thicker than
200 lm in diameter [9, 30]. Neovascularization has been
attempted by culturing cardiac tissues in highly vascular areas
in vivo, such as the omentum [34]. Others have used hydrogels
from dissolved omentum, with potential use for 3D bioprinted
cardiac tissues [5, 44]. However, to date, only capillary-sized, dis-
organized vasculature has been generated and recreating a fully
branched vascular network for cardiac tissue engineering remains
a challenge (Fig. 3) [4–6, 9, 10, 19, 49].
Figure 3: Vascularization in tissue-engineered cardiac patches. (A) CD31 expression (green) in a cardiac patch generated by a fibrinogen moulding method and
engrafted in pigs (modified with permission from Gao et al. [4]). (B) CD31 expression (green) in a cardiac patch generated by a net moulding method and engrafted in
rats (modified with permission from Yang et al. [19]). (C) CD31 expression (red) in a fibrin-based cardiac patch generated by a spheroid fusion method and engrafted
in mice (modified with permission from Mattapally et al. [6]). (D) CD31 expression (green) in a cardiac patch generated by a 3-dimensional bioprinting method (modi-
fied with permission from Noor et al. [5]). (E) CD31 expression (red) in a cardiac patch generated by a 3-dimensional bioprinting method (modified with permission
from Zhang et al. [10]). (F) vWF (red) and lamin A/C (green) expressions in a cardiac patch generated by a 3-dimensional bioprinting method and engrafted in mice
with the evidence of host-patch anastomosis (modified with permission from Maiullari et al. [9]). Scale bar appearances are due to source data. vWF: von Willebrand
factor.
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Further progress is being made in engineering vascularized tis-
sues by co-culturing CMs with ECs. For example, a microvascular
network was achieved in spheroid cultures containing rat ECs,
CMs and fibroblasts before their implantation in nude rats [52]. It
has been suggested that a better branched vascular network
could be achieved by fusing prevascularized spheroids [20, 39,
43]. Vascular network anastomosis between graft and host in vivo
is critical for new blood flow to promote the engraftment and
function of transplanted patches [7, 9, 20, 39, 53]. At a cellular
level, such graft–host anastomoses may form directly, for in-
stance by a ‘wrap and tap’ mechanism whereby graft lumen-
forming ECs anastomose with host vasculature by wrapping
around host vessels and ‘tapping’ through the vessel walls, facili-
tated by matrix metalloproteases [54]. Paracrine signalling includ-
ing a ‘secretome’ of cytokines, exosomes and growth factors such
as vascular endothelial growth factor is a major regulator of tissue
angiogenesis and potentially of cardiac regeneration [4, 9, 23, 48,
55].
The emerging evidence that regenerative transplanted tissue
may act by mechanisms other than direct replenishment of lost
cells would explain why functional improvement has been seen
for patches containing only 8 million cells [4, 33]. It would be ad-
vantageous if paracrine mechanisms turned out to be more im-
portant than numerical replenishment, as another major
challenge is how to expand replacement cells, including non-
myocytes (such as ECs and CFs) and myocytes, to a high enough
number [3, 40].
An alternative method to bioprinted cardiac tissues is to pre-
form a vascular scaffold. This may be bioprinted in patterns such
as networks by depositing cellular bioink [8, 10, 49]. For example,
Zhang et al. [49] used microfluidic printheads to bioprint ECs
within hydrogels. These were fixed in position by ionic and ultra-
violet (UV) light crosslinking. The ionic crosslinker (calcium chlor-
ide) was added to the alginate scaffold in real time during the
print, followed by UV crosslinking of gelatin methacryloyl.
Following formation of a vascularized scaffold, CMs were added
to the construct to generate cardiac tissue.
CONTRACTILE FUNCTION
For myocardial tissue to first engraft in the host and eventually
improve cardiac function, it should not only synchronously con-
tract by itself but also together as a functional syncytium with the
host [40]. Electrical properties of cells and tissues, such as cardiac
excitation-contraction coupling, calcium transients and cell–cell
interactions, are critical [1, 40, 51]. iPSC-CMs do not present the
fully mature contractile behaviour typical of adult cells, unless
they are cultured with additional cellular and extracellular stimuli,
such as electromechanical conditioning, electrical field stimula-
tion and continuous pacing (Fig. 4 and Videos 1 and 2) [21, 56].
Cardiac spheroids from iPSC-CMs spontaneously develop syn-
chronous contractile function, which is linked with improved
speed and amplitude of contraction, and calcium transients com-
pared to single-cell cultures [1, 36, 42]. Adding conductive poly-
mers propagates the electrical signal between different areas in a
cell culture, providing assistance with current passage in the ab-
sence of fully developed cell–cell electrochemical pathways [51,
57]. Overall, physiological contractile function and integration of
engineered tissue with the host remain some of the main chal-
lenges to overcome (Table 1) [1, 21, 56].
PRECLINICAL SUCCESS
In animal models of myocardial infarction, functional improve-
ment after the engraftment of heart patches generated from cells
in moulding devices has already been demonstrated in mice [6],
rats [19] and pigs [4]. Direct injection of hydrogel laden with
paracrine signalling factors has shown a significant reduction in
infarct size from 38% to 16% in a rat model of myocardial infarc-
tion [48]. Furthermore, a small rat-sized cardiac ventricle (1/
250th the size of a human ventricle) has been tissue-engineered
by MacQueen et al. [58]. However, this only approximated 100
millionth (-108) of the contractile work of a native human ven-
tricle. Indeed, at 1%, the ejection fraction of this model was
1/50th of a normal rat’s ejection fraction and the cell density
was 10-fold less than normal for a rat. Other studies that used 3D
bioprinting reported improved cardiac patch vascularization,
automation and precision in vitro and in vivo in mice [5, 9, 10].
These studies provide examples demonstrating significant pre-
clinical progress and pave the way for human trials and scaled up
models.
SURGICAL PERSPECTIVES
Whilst surgical treatment of aortic, coronary and valve disease
can now be undertaken with excellent results, repair or recon-
struction of the contractile pump element, the myocardium, is
currently limited [2]. Excluding infrequently performed proce-
dures such as the Dor (pericardial-lined Dacron endoventricular
circular plasty) [59] and Batista (reduction ventriculoplasty) [60]
procedures, the only option beyond resynchronization is trans-
plantation [7]. Whether this is human or genetically modified
xenotransplantation, the loss of the recipient’s heart is obligatory
and absolute dependence on the function of the new heart fol-
lows. Cellular cardiomyoplasty has been evaluated to allow the
augmentation of existing cardiac function but, despite showing
some functional merit, has largely been disappointing overall
[23].
Early clinical trials using ESC-derived cardiac cells in patients
have shown promising results by culturing cells in a patch before
transplantation [33, 61]. Following the first case report of a cellu-
lar patch applied to a human heart in 2015 [61], the same group
reported that transplantation of these patches in 6 patients with
heart failure is safe (the ESCORT trial) [33]. Cardiac patches of
20 cm2 were surgically applied to the epicardium of patients
undergoing coronary artery bypass surgery and secured under a
pericardial flap (Fig. 5). As the patches were not 3D bioprinted,
the advantages of a scalable manufacturing process were not
present; nonetheless, the trial paved the way for more extensive
trials testing efficacy.
With prevascularized patches, the study by Maiullari et al. [9]
showed that host-patch anastomosis in mice is feasible using 3D
bioprinted poly(ethylene glycol)-fibrinogen hydrogels embedded
with iPSC-CMs and human umbilical vein ECs (Fig. 3F). An aug-
mentative approach may be the use of pro-angiogenic factors to
promote vascular fusion between graft and host, similar to that
which is observed during vascular development [43].
To progress with the transplantation of thick bioprinted heart
tissues with potentially low-calibre vasculature in patients, the
surgeon may be tasked with creating a macroscopic anastomosis
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be true if naturally forming low-calibre anastomoses to the dis-
eased native myocardial tissue underneath the graft were insuffi-
cient. Foreseeably, microsurgical anastomoses may have to be
made initially to allow time for naturally occurring graft–host
connections to form [53].
One approach to promote host-patch vascular anastomosis
could be to use non-diseased, larger-calibre source vessels such
as the gastroepiploic or thoracodorsal artery with the tissue culti-
vated on the omentum or the latissimus dorsi muscle, respective-
ly. Bioengineered tissue could be allowed time to form
anastomoses with the underlying tissue, and capillaries formed
from ECs within a tissue-engineered cardiac patch can retain pa-
tency [53]. Blood flow through the graft could be assessed in ad-
vance whilst it lay on its incubating native tissue. Once blood
flow and viability of the patch are demonstrated, it should be
surgically feasible to then rotate a flap to the myocardium within
the pericardium without loss of blood supply (Fig. 6).
Conversely, minimally invasive procedures could be used to
transplant bioprinted cardiac tissues in innovative ways for car-
diac surgical patients [62].
Figure 4: Electrical stimulation of cell culture leads to greater contractility in engineered cardiac tissue. Beating macrotissues were generated by seeding induced pluri-
potent stem cell-derived cardiomyocytes and human fibroblasts in a 3-dimensional porous scaffold and culturing for 14 days as either control (no electrical stimula-
tion) or ‘CardioSlice’ (electrical stimulation applied whilst culturing). (A) Human cardiac macrotissues after 7 or 14 days of culture, either without (control) or with
(CardioSlice) electrical stimulation (scale bars 2.5 mm) (see also Videos 1 and 2). (B) Contraction amplitude of control versus CardioSlice bioengineered cardiac tissues.
Fractional contraction area (compared to area of the tissue at rest) is represented over time, and control tissue remains close to 1.0 when contracting whereas
CardioSlice patches contract to 0.85 (85% of size of tissue at rest). (C) The percentage of FAC for control (unstimulated) versus electrically stimulated CardioSlice car-
diac macrotissues. (D) MCR for control compared to electrically stimulated CardioSlice macrotissues when paced. At 14 days, CardioSlice macrotissues were able to
be paced at over 4 Hz, approximately double the MCR of control tissues. (E) Beating cardiac macrotissue velocity maps after 14 days of culture. Blue colours and
shorter white mini arrows represent lower velocities. Higher velocities (redder areas and longer mini arrows) were observed in CardioSlice macrotissues versus con-
trols (scale bar 2.5 mm). (F) Alignment analysis comparing direction of the electrical field vector and subsequent beating direction of bioengineered cardiac tissues.
The order parameter cos2h was used: random distribution gives values close to 0 whereas parallel alignment gives values close to 1 (modified with permission from
Valls-Margarit et al. [21]). FAC: fractional area change; MCR: maximum capture rate.










As is expected when multiple emerging technologies/techniques
(iPSCs, 3D culture, bioprinting) make rapid preclinical gains,
translation of the preclinical potential into a useful clinical thera-
peutic presents specific challenges [40, 63, 64]. Laboratory work-
flows for autologous iPSCs are appealing in offering a fully
patient-specific supply of tissue; however, they can be relatively
difficult and resource intensive to achieve for 1 patient per work-
flow [23]. For translation, workflows need to conform to good
manufacturing practice standards, usually making them more
challenging, for example, by replacing commonly used xenogen-
eic laboratory products such as foetal bovine serum with human
serum album or carrying out the work in a fully certified good
manufacturing practice facility [63, 64]. An alternative, using allo-
geneic iPSCs from donors, comes with the advantage of poten-
tially being able to cryobank multiple haplotyped iPSCs and
iPSC-derived cells or tissues [23, 40]. Having the cells banked in
cold storage could allow for a more technically, logistically and
economically feasible solution: an ‘off-the-shelf’ selection of a
best-matched tissue at the time of need [23, 40]. However, this
would be accompanied with immunosuppression, difficulties
acquiring matched tissue (especially for diverse ethnic groups)
and a likely need for international coordination for a large
enough tissue repository [23, 40].
DISCUSSION
Whilst 3D bioprinting of a fully functional human myocardial
patch has not yet been achieved, there are several areas where
3D bioprinting of other tissues has already reached clinical trials.
For example, 3D bioprinting of ears of 5 children showed
promising results up to 2.5 years of follow-up [65]. However, 3D
bioprinting of heart patches presents a different level of
complexity.
Important questions remain regarding the application of
bioprinted tissue for human cardiac surgery and the patient
population it will most benefit [2, 3]. Whether advances in
other technologies, such as ventricular assist devices, or even a
refined surgical plication technique, could be combined with
bioprinted heart tissue in innovative ways remains an open
question.
Throughout this review, there has been an assumption that the
optimal microenvironment of cardiac tissue should be achieved,
but this may not be required and good results may be obtained
even in the absence of cells [55, 62]. Recently, a study showed
that macrophages may play a major role in cardiac regeneration
by inducing inflammation following stem cell injection [66]. It is
possible that mechanisms such as this could be implicated in the
surprising finding that even acellular patches or hydrogels
applied to the heart may have a positive effect on cardiac regen-
eration via the immune response [55, 62]. Nevertheless, any for-
eign material or cells within a patch will lead to an immune
response with a rim of fibrosis, potentially isolating the graft from
the host [40]. Therefore, a better understanding of these mecha-
nisms may be beneficial to developing novel approaches to bet-
ter couple the graft with the host. These may include the use of
either conductive polymers (to allow electroactivity to bypass the
fibrotic rim) [57], sacrificial hydrogels disintegrating over time [8,
53] or adjunctive anti-inflammatory and/or ‘pro-survival’ com-
pounds [67, 68].
It would be critical to compare the cost-effectiveness of a stem
cell-derived 3D bioprinted cellular patch to other techniques for
long-term treatment but with the price of bioprinters falling rap-
idly [38], cells derived from patients themselves and workflows
utilizing basic laboratory materials [1, 47], there is reason to
speculate that 3D bioprinted patient-specific multicellular
patches could be a cost-effective surgical therapeutic.
For end-stage cardiac pathology, this is one of the few emerg-
ing technologies that provides hope of a cure. It is unique in that
it may offer a paradigm-shifting solution for patients with cardiac
failure who could otherwise only be ‘cured’ with a heart trans-
plant. This potential generates considerable media attention
which raises specific ethical considerations. These are only re-
cently being elucidated in the bioethical literature, for example,
how media hype can inflate expections for desperate patients,
which may also create an environment for unscrupulous health
providers, or how public misinformation may impact patients’
decision-making significantly [63, 69]. Safe translation of animal
Video 1: Bioengineered human cardiac tissue showing spontaneous beating
after 14 days in culture—non-stimulated control tissue shown (reproduced with
permission from Valls-Margarit et al. [21]).
Video 2: Bioengineered human cardiac tissue showing spontaneous beating
after 14 days in culture—electrically stimulated (CardioSlice) tissue shown
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to human trials may require new 3D bioprinting-specific regula-
tion [69].
CONCLUSION
For patients with non-functional areas of myocardium, 3D bio-
printing of personalized heart tissues presents several challenges
but also the potential to develop a clinically available approach
in the coming years. If successful, this technology has the
potential to re-shape the cardiac therapeutic environment,
resolve an unmet need for surgical practice and actualize a
long-standing desire for surgeons to promote cardiac regener-
ation in patients.
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